Form 8-K

8-K — BICYCLE THERAPEUTICS PLC

Accession: 0001104659-26-052107

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001761612

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2613019d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613019d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613019d1_8k.htm · Sequence: 1

false

0001761612

00-0000000

true

0001761612

2026-04-30

0001761612

us-gaap:CommonStockMember

2026-04-30

0001761612

bcyc:AmericanDepositarySharesMember

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section

13 or 15(d) of the Securities Exchange Act of 1934

April 30, 2026

Date of Report (Date of earliest event reported)

Bicycle

Therapeutics plc

(Exact name of registrant as specified in its

charter)

England

and Wales

001-38916

Not

applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Blocks

A & B, Portway Building,

Granta

Park Great Abington, Cambridge

United Kingdom

CB21

6GS

(Address of principal

executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +44

1223 261503

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title

of each class

Trading

Symbol (s)

Name

of each exchange on which registered

Ordinary

shares, nominal value £0.01 per share

n/a

The

Nasdaq

Stock Market LLC*

American

Depositary Shares, each representing one ordinary share, nominal value £0.01 per share

BCYC

The

Nasdaq

Stock Market LLC

* Not

for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.

Results of Operations and Financial Condition

On April 30, 2026, Bicycle Therapeutics plc issued a press release

announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights. A copy of the press release is

being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 in this Current Report

on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed

incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth

by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release issued April 30, 2026

104

Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Date: April 30, 2026

BICYCLE THERAPEUTICS PLC

By:

/s/ Travis Thompson

Name:

Travis Thompson

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613019d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Bicycle Therapeutics Reports Recent Business

Progress and First Quarter 2026 Financial Results

Presentations at AACR Annual Meeting 2026 underscore

significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer

Human imaging data provides further evidence

of the potential of EphA2 as a novel cancer target and the positive properties of Bicycle® radioligand molecules for radiopharmaceutical

use

Initial dose selection data from Duravelo-2

trial evaluating zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer to be presented at 2026 ASCO Annual Meeting

Cash and cash equivalents of $559.5 million

as of March 31, 2026, with expected cash runway into 2030

CAMBRIDGE, England & BOSTON, April 30, 2026

– Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based

on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended

March 31, 2026, and provided recent corporate updates.

“The data we reported in the first

quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology therapeutics with

improved benefit/risk profiles compared to existing modalities,” said Bicycle CEO Kevin Lee, Ph.D. “We are excited by

the emerging profile of our EphA2 drug conjugate, nuzefatide pevedotin, which we have now tested in over 150 patients to date, both

as a monotherapy and in combination with a checkpoint inhibitor. Nuzefatide has been shown to be generally well tolerated at

clinically active doses, in contrast to previous attempts to drug this target with other modalities. We believe these data, together

with those presented at AACR, provide a strong rationale for advancing the development of nuzefatide in pancreatic cancer, and we

are pleased to have recently dosed our first patient in our Phase 2 trial. In addition to this, the preliminary data we have reported from our Duravelo-2 program demonstrate zelenectide pevedotin to also be clinically

active with a differentiated safety profile, providing convincing evidence that Bicycle drug conjugates may exhibit a fundamentally different

tolerability profile to that seen with antibody-based approaches, and support our mission of helping patients not only to live longer

but also to live well.”

Dr. Lee added: “Following a strategic

reprioritization in the first quarter, we are converting the Duravelo-2 trial into a randomized Phase 2 trial, allowing us to focus

our internal resources on our emerging pipeline of next-generation therapeutics, including nuzefatide and Bicycle-based

radiotherapeutics and imaging agents. We look forward to presenting initial dose selection data from our Duravelo-2 trial at the

upcoming 2026 ASCO Annual Meeting and will continue to evaluate the best path for this program as the data continues to

mature.”

First Quarter 2026 and Recent Events

· Data presented at the American Association

for Cancer Research (AACR) Annual Meeting 2026 demonstrates significant opportunities for nuzefatide pevedotin (nuzefatide), formerly

BT5528, a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), in EphA2 expressing

cancers.

o Nuzefatide Phase 1/2 data show a differentiated safety profile in combination with nivolumab in metastatic

urothelial cancer (mUC) patients as well as promising anti-tumor activity. As of the February 9, 2026 data cutoff, results from the Phase

1/2 trial evaluating nuzefatide 6.5mg/m2 once every two weeks (Q2W) plus nivolumab 480mg once every four weeks (Q4W) in 14

patients with mUC who had previously progressed on a checkpoint inhibitor (10 while on enfortumab vedotin) showed:

· 40% confirmed overall response rate (ORR) (4/10) among patients with EphA2+

tumors and 100% confirmed ORR (3/3) among patients with EphA2+ tumors that were monomethyl auristatin E (MMAE)-naïve.

· Patients who achieved a partial response (PR) or at least 16 weeks of stable

disease (SD) were on treatment for a minimum of 56 weeks and most continued on treatment at the time of the data cut-off.

· Nuzefatide in combination with nivolumab was generally well tolerated with

no Grade ≥3 treatment-related adverse events (TRAEs) of clinical interest and no TRAEs of hemorrhage observed. Only one dose-limiting

toxicity of Grade 3 fatigue that lasted for five days was reported and improved to Grade 1 without dose reduction.

o Preclinical assessment of nuzefatide anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma

(PDAC). Expression of EphA2 was found in all 16 PDAC PDX models. Of the 14 PDAC PDX models assessed for anti-tumor activity, 10 models

were sensitive to nuzefatide, six of which showed high sensitivity.

o Preclinical assessment of nuzefatide anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell

carcinoma (HNSCC). Nuzefatide demonstrated potent preclinical anti-tumor activity in EphA2-expressing CDX models of HNSCC.

Altogether, Bicycle Therapeutics believes

that these data highlight significant opportunities for nuzefatide in EphA2 expressing cancers, including pancreatic cancer.

In March 2026, Bicycle Therapeutics

began enrolling a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent

PDAC, and the first patient was successfully dosed in April 2026. Bicycle Therapeutics has determined 8mg/m2 Q2W as the preferred

dose for the trial.

· Additional human imaging data of a Bicycle®

Imaging Agent (BIA) targeting EphA2 in patients with PDAC presented at AACR Annual Meeting 2026. The German Cancer Consortium (DKTK),

part of a cooperative network with the German Cancer Research Center (DKFZ), presented human imaging data conducted with a Bicycle molecule

targeting EphA2 labelled with gallium-68 (EphA2 BIA). Seven patients with histologically confirmed PDAC underwent PET/CT imaging up to

three hours post injection of the EphA2 BIA. Data demonstrated rapid tumor uptake in six out of seven patients with excretion primarily

via the kidneys. EphA2 BIA PET imaging successfully detected multiple liver, bone, lymph node, and peritoneal metastases.

These data are representative of the

results seen in 15 out of 18 patients with PDAC who have undergone EphA2 BIA imaging to date. Bicycle Therapeutics believes these data

validate the potential of EphA2 as a novel target in the treatment of cancer, demonstrate the translatability of preclinical data and

highlight the potential of Bicycle® molecules for targeted radioligand therapies and radiopharmaceutical imaging.

· Promising Duravelo-2 data and multiple potential

regulatory pathways provide a range of options for a Phase 3 trial and potential commercialization of zelenectide pevedotin (zelenectide)

in mUC. Initial dose selection data from the Duravelo-2 trial demonstrate response rates comparable to those published for existing

standards of care, with physician assessed ORR of 65%, blinded independent central review (BICR) confirmed ORR of 58% at the 27-week cutoff

and a differentiated safety profile. Subsequent to the 27-week cutoff, an additional confirmed BICR response was observed, which would

result in an ORR of 62%. Zelenectide at 6mg/m2 two weeks on, one week off demonstrated a differentiated safety profile with

only one patient discontinuing therapy due to a TRAE at the 27-week cutoff.

While Bicycle Therapeutics evaluates

preliminary regulatory feedback from the European Medicines Agency, U.S. Food and Drug Administration (FDA), and Medicines and Healthcare

products Regulatory Agency, and the potential paths for this program, the company is converting the ongoing Duravelo-2 trial to a randomized

Phase 2 trial and deprioritized the program for internal development.

Bicycle Therapeutics will present initial

Duravelo-2 dose selection data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in

Chicago.

· Strategic reprioritization focuses on promising

pipeline of next-generation therapeutics. In March 2026, Bicycle Therapeutics initiated a strategic reprioritization in order to focus

its resources on its promising pipeline of next-generation therapeutics, including nuzefatide, as well as its emerging Bicycle conjugate

pipeline, including BRCs. As part of the reprioritization, Bicycle Therapeutics seeks to discontinue the Phase 1/2 Duravelo-3 trial for

zelenectide in NECTIN4-amplified breast cancer and the Phase 1/2 Duravelo-4 trial for zelenectide in NECTIN4-amplified non-small cell

lung cancer. Enrollment for these trials is closed, and patients currently enrolled will complete their course of treatment. In addition, Bicycle

Therapeutics announced a workforce reduction pursuant to which it expects to reduce its workforce by approximately 30%. Anticipated

annual operational savings related to the workforce reduction and strategic reprioritization are expected to reduce annual operating expenses

by approximately 50% based on the company’s current plans. These actions are expected to extend Bicycle Therapeutics’ cash

runway by approximately two years, into 2030.

First Quarter 2026 Financial Results

· Cash and cash equivalents were $559.5 million

as of March 31, 2026, compared to $628.1 million as of December 31, 2025. The decrease in cash and cash equivalents is primarily due to

cash used in operations, including cash payments for clinical program activities.

· Collaboration revenue was $0.9 million for the

three months ended March 31, 2026, compared to $10.0 million for the three months ended March 31, 2025. The decrease in collaboration

revenue of $9.1 million was primarily due to the termination of our collaboration programs with Genentech and Novartis.

· Research and development (R&D) expenses were $48.9

million for the three months ended March 31, 2026, compared to $59.1 million for the three months ended March 31, 2025. The decrease

in expense of $10.2 million was primarily due to decreased clinical program expenses for zelenectide and share-based compensation due

to our workforce reduction, offset by lower U.K. R&D tax credits period over period.

· General and administrative (G&A) expenses

were $17.5 million for the three months ended March 31, 2026, compared to $21.1 million for the three months ended March 31, 2025.

The decrease in expense of $3.6 million was primarily due to decreased professional and consulting fees and decreased share-based compensation

due to our workforce reduction.

· Net loss was $60.8 million, or $(0.87)

basic and diluted net loss per share, for the three months ended March 31, 2026, compared to net loss of $60.8 million, or $(0.88)

basic and diluted net loss per share, for the three months ended March 31, 2025.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage

pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that

are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds

to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity,

making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528,

a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of

other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical

use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; BT7480, a Bicycle

Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137; and, through

various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional

therapeutic areas.

Bicycle Therapeutics is headquartered in Cambridge,

UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking

statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may

be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,”

“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”

“potential,” “seeks,” “will” and variations of these words or similar expressions that are intended

to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in

this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of nuzefatide pevedotin,

including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and

the potential development of nuzefatide pevedotin in a number of cancers, including pancreatic cancer; the progress of Bicycle Therapeutics’

clinical trials, reporting data from Bicycle Therapeutics’ clinical trials, including for nuzefatide pevedotin, the timing of EphA2

human imaging data and updates on future clinical development plans for nuzefatide pevedotin; the potential of EphA2 as a novel cancer

target and the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use; the development of the

Bicycle® radioligands pipeline, including BRCs and BIAs; the potential benefits of Bicycle Therapeutics’ strategic

reprioritization, including the potential extension of financial runway; the workforce reduction and its impact on Bicycle Therapeutics’

expenditures; communications with and feedback from the FDA and other regulatory agencies including the potential for multiple regulatory

pathways for zelenectide pevedotin in mUC; the existence of a range of options for a Phase 3 trial and potential commercialization of

zelenectide pevedotin in mUC; Bicycle Therapeutics’ expected financial runway; and the use of Bicycle Therapeutics’ technology

through various partnerships to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics may not

actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue

reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations

disclosed in these forward-looking statements as a result of various factors, including: the workforce reduction may take longer or result

in more significant charges or cash expenditures than anticipated or otherwise negatively impact Bicycle Therapeutics’ and its

business plans during and after the period during which the workforce reduction is being executed; uncertainties related to the benefits

of the strategic reprioritization; uncertainties inherent in research and development and in the initiation, progress and completion

of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics

may not realize the intended benefits of its technology or partnerships; the risk that Bicycle Therapeutics may not achieve any of its

clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical

trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse

effects arising from the testing or use of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics’

projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated;

and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the

forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle Therapeutics’

Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 17, 2026, as well as in other

filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this

press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking

statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise

required by law.

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations

and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

March 31,

2026

2025

Collaboration revenue

$ 887

$ 9,977

Operating expenses:

Research and development

48,901

59,058

General and administrative

17,468

21,123

Total operating expenses

66,369

80,181

Loss from operations

(65,482 )

(70,204 )

Other income (expense):

Interest and other income

4,877

8,414

Interest expense

(48 )

(51 )

Total other income, net

4,829

8,363

Net loss before income tax provision

(60,653 )

(61,841 )

Provision for (benefit from) income taxes

172

(1,087 )

Net loss

$ (60,825 )

$ (60,764 )

Net loss per share, basic and diluted

$ (0.87 )

$ (0.88 )

Weighted average ordinary shares outstanding, basic and diluted

69,683,471

69,196,945

Balance Sheets Data

(In thousands)

(Unaudited)

March 31,

December 31,

2026

2025

Cash and cash equivalents

$ 559,474

$ 628,110

Working capital

570,246

625,901

Total assets

652,396

717,597

Total shareholders’ equity

554,320

609,977

Investors:

Matthew DeYoung

Argot Partners

ir@bicycletx.com

212-600-1902

Media:

Argot Partners

media@bicycletx.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 30, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-38916

Entity Registrant Name

Bicycle

Therapeutics plc

Entity Central Index Key

0001761612

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Blocks

A & B, Portway Building

Entity Address, Address Line Two

Granta

Park Great Abington

Entity Address, City or Town

Cambridge

Entity Address, Country

Entity Address, Postal Zip Code

CB21

6GS

City Area Code

+44

Local Phone Number

1223 261503

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member]

Title of 12(b) Security

Ordinary

shares, nominal value £0.01 per share

No Trading Symbol Flag

true

Security Exchange Name

NASDAQ

American Depositary Shares [Member]

Title of 12(b) Security

American

Depositary Shares, each representing one ordinary share, nominal value £0.01 per share

Trading Symbol

BCYC

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bcyc_AmericanDepositarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: